What is she best known for?
The fields of study she is best known for:
- Gene
- Cancer
- Internal medicine
Her main research concerns Breast cancer, Internal medicine, Oncology, Genome-wide association study and Genetics.
The study incorporates disciplines such as Single-nucleotide polymorphism and Genotype in addition to Breast cancer.
Rita K. Schmutzler usually deals with Internal medicine and limits it to topics linked to Olaparib and Iniparib, PARP inhibitor and Tolerability.
Her Oncology research incorporates themes from Gene mutation, Gynecology, Ovarian cancer, Prospective cohort study and Prostate cancer.
Rita K. Schmutzler combines subjects such as Mendelian randomization, Disease, Genetic predisposition, Bioinformatics and Genetic association with her study of Genome-wide association study.
Her Genotyping, Locus, Genetic variation and Missense mutation study in the realm of Genetics connects with subjects such as UBA1.
Her most cited work include:
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial (1797 citations)
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer (1152 citations)
- Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation (998 citations)
What are the main themes of her work throughout her whole career to date?
Breast cancer, Internal medicine, Oncology, Genetics and Cancer are her primary areas of study.
She has researched Breast cancer in several fields, including Cancer research, Genome-wide association study, Genotype, Single-nucleotide polymorphism and Ovarian cancer.
As a member of one scientific family, Rita K. Schmutzler mostly works in the field of Ovarian cancer, focusing on Genetic testing and, on occasion, Genetic counseling.
Her Internal medicine research incorporates elements of Germline mutation and Gynecology.
As a part of the same scientific family, Rita K. Schmutzler mostly works in the field of Oncology, focusing on Hazard ratio and, on occasion, Proportional hazards model.
Her Cancer research includes themes of Disease and Pathology.
She most often published in these fields:
- Breast cancer (71.22%)
- Internal medicine (40.53%)
- Oncology (37.17%)
What were the highlights of her more recent work (between 2018-2021)?
- Breast cancer (71.22%)
- Internal medicine (40.53%)
- Oncology (37.17%)
In recent papers she was focusing on the following fields of study:
Breast cancer, Internal medicine, Oncology, Ovarian cancer and Germline mutation are her primary areas of study.
Her Breast cancer research is under the purview of Cancer.
Her Internal medicine study frequently draws connections to other fields, such as Mutation.
Her research in Oncology tackles topics such as Hazard ratio which are related to areas like Single-nucleotide polymorphism, Proportional hazards model, Cohort study and Genome-wide association study.
The various areas that Rita K. Schmutzler examines in her Germline mutation study include Prostate, Therapy response and Early breast cancer.
Her Cancer research research includes elements of EZH2, Fanconi anemia and Olaparib.
Between 2018 and 2021, her most popular works were:
- Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes (257 citations)
- Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families (68 citations)
- Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers (40 citations)
In her most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Rita K. Schmutzler mainly focuses on Breast cancer, Internal medicine, Oncology, Prospective cohort study and Germline mutation.
Her study in Breast cancer focuses on Estrogen receptor in particular.
Her study looks at the relationship between Estrogen receptor and fields such as Genome-wide association study, as well as how they intersect with chemical problems.
She interconnects Single-nucleotide polymorphism and PALB2 in the investigation of issues within Internal medicine.
Her research integrates issues of Odds ratio, Cancer, Prostate cancer, Genetic counseling and Genetic testing in her study of Oncology.
Her biological study spans a wide range of topics, including Incidence, Cohort study and Mutation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
